Jefferies Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $71
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Jefferies analyst Roger Song maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $58 to $71.
Jefferies analyst Roger Song maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $58 to $71.